Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?. (17th November 2020) - Heinen, André; Schnabel, Anja; Brück, Normi; Smitka, Martin; Wolf, Christine; Lucas, Nadja; Dollinger, Stefanie; Hahn, Gabriele; Günther, Claudia; Berner, Reinhard; Lee-Kirsch, Min Ae; Schuetz, Catharina